NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

ICON Public Limited Company (ICLR) Stock Analysis

ICON Public Limited Company (ICLR) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ICLR

$185.25

+$11.06 (+6.35%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ICLR with… →

ICLR Key Statistics

As of Oct 21, 2026
Trading
Open
$171.54
Previous Close
$174.19
Day's Range
171.54–188.27
52-Week Range
66.57–203.91
Volume
1.16M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.24
Valuation
Market Cap
$14.29B
P/E Ratio
195.00
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.74
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.53
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.72
EPS (ttm)Profit attributable to each share over the last twelve months.
0.95
Financials (FY)
Revenue (FY)
$8.25B+0.76%
Net Income (FY)
$229.34M−68.97%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
77.15M
1-Year Return
−4.14%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
853.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ICLR closed at $185.25, −4.14% over 1 year.

ICON Public Limited Company (ICLR) has a market capitalization of $14.29B.

In fiscal 2025, ICLR reported revenue of $8.25B.

ICLR Stock Return by Calendar Year

ICON Public Limited Company (ICLR) 10-year return: what $10,000 became

1 year
$10,000 $9,586
−4.14%
5 years
$10,000 $6,685
−33.15%
10 years
$10,000 $21,913
+119.13%

If you had invested $10,000 in ICON Public Limited Company (ICLR) 10 years ago, at the close on October 21, 2016, it would have been worth $21,913 at the close on October 21, 2026: +119.13% in total, +8.16% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.66%
2025−13.11%
2024−25.92%
2023+45.72%
2022−37.28%
2021+58.84%
2020+13.21%
2019+33.29%
2018+15.21%
2017+49.14%
2016 (partial year)−0.21%

As of October 21, 2026.

ICLR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$8.25B$229.34M2.8%
2024$8.19B$739.13M9.0%
2023$8.05B$554.21M6.9%
2022$7.74B$505.30M6.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$8.25B$2.18B$1.01B$229.34M2.8%
2024$8.19B$2.37B$1.15B$739.13M9.0%
2023$8.05B$2.35B$994.23M$554.21M6.9%
2022$7.74B$2.21B$866.08M$505.30M6.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ICLR Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricICLRDiagnostics & Research medianvs median
P/E195.0037.595.2x the median
P/S ratio1.725.230.3x the median
Profit margin0.33%−0.93%1.3 pts above

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ICON Public Limited Company (ICLR) carries a market capitalisation of $14.29B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 40,200 employees.

The 52-week range on file runs from $66.57 to $203.91. ICLR last closed at $185.25 on October 21, 2026. That is +$11.06 (+6.35%) against the previous close. The latest close sits 178.28% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $8.25B. Against the prior fiscal year total of $8.19B, that is a change of +0.76%. The same year closed with net income of $229.34M. That is −68.97% against the prior fiscal year. The reported profit margin is 0.33%. That is 1.3 percentage points above the Diagnostics & Research median of −0.93%. Earnings per share on a trailing basis come to 0.95.

Across the 4 fiscal years on file, revenue moves from $7.74B in 2022 to $8.25B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 195 times earnings. That is 5.2 times the Diagnostics & Research median of 37.59. On forward earnings the ratio is 15.74. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.53. Measured against sales, the shares trade at 1.72 times revenue. On price-to-sales that is 0.3 times the Diagnostics & Research median of 5.23. The medians here are taken across 45 Diagnostics & Research companies that report the metric.

Over the trailing twelve months the total return is −4.14%. Across 10 years the annualized return works out at +8.16%. The reported beta is 1.24. Annualized volatility over the trailing 10 years is 38.45%.

Growth & Income

No dividend is on file for ICLR.

So far in 2026 the total return is +1.66%. The strongest complete calendar year on file is 2021 at +58.84%; the weakest is 2022 at −37.28%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

ICON Public Limited Company (ICLR) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ICON Public Limited Company ICLR $14.29B 195.0
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. ICON Public Limited Company trades at a P/E of 195.0.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About ICON Public Limited Company

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Visit website →